



DR. DEBORAH PALESTRANT JOINS 5AM VENTURES AS PARTNER, HEAD OF 4:59

Further 5AM team expansion includes Venture Partner Dr. Elliot Ehrich and General Counsel Dr. Galya Blachman

San Francisco, CA, November 13, 2018 - 5AM Ventures of San Francisco, CA and Boston, MA is pleased to announce the addition of Deborah Palestrant, Ph.D., M.B.A., as Partner and Head of 4:59, the company's internal newco formation initiative. "We are thrilled to welcome Deb to the 5AM leadership team," said Kush Parmar, Managing Partner. "She brings 15 years of industry experience ranging from drug discovery and company creation, to operations and business development. We are excited for her to take the 4:59 helm."

Dr. Palestrant was previously the Vice President of Corporate Development & Strategy at Relay Therapeutics. Prior to Relay Tx, she led the business development team at Editas Medicine (NASDAQ: EDIT) from its inception. Her extensive experience includes advancing multiple structure-based drug discovery programs as a former lab head at the Novartis Institutes for Biomedical Research and helping to build and launch both Blueprint Medicines (NASDAQ: BPMC) and Editas Medicine while at Third Rock Ventures. Dr. Palestrant holds a Ph.D. in biochemistry and molecular biophysics from Columbia University, an M.B.A from Northeastern University, and was a Damon Runyon Cancer Research Foundation Postdoctoral Fellow at The Scripps Research Institute.

5AM has also expanded its roster of consulting Venture Partners with the addition of Elliot Ehrich, M.D.. Dr. Ehrich was recently appointed as Chief Medical Officer of Expansion Therapeutics, a 5AM cofounded and seeded newco spun out of its 4:59 initiative. He brings over 25 years of drug development experience, including the last eighteen years at Alkermes, plc, as Executive Vice President, R&D and Chief Medical Officer, and previous experience at Merck & Co, Inc. working in clinical pharmacology and clinical development. Dr. Ehrich directed the development and successful FDA registration of VIVITROL® and ARISTADA® and partnered the development of RISPERDAL CONSTA® and BYDUREON®. Dr. Ehrich completed a postdoctoral fellowship in immunology at Stanford University, holds an M.D. degree from Columbia University and a B.A. degree from Princeton University.

Galya Blachman, Ph.D., joins 5AM as General Counsel and Compliance Director. Dr. Blachman was previously on the Legal R&D transactions team at AbbVie and a Director in the legal group of Stemcentrx before it was acquired in 2016. Dr. Blachman began her career at Slaughter & May and practiced intellectual property law at Simmons & Simmons. She currently serves as the General Counsel at Biotech Connection Bay Area, a non-profit that focuses on career development for academic scientists. Dr. Blachman received her law degree in England and completed a postgraduate diploma in intellectual property law from Oxford University. She earned a Ph.D. in Pharmacology from Cambridge University and an M.Sc. in Pharmacology from the University of Cape Town, South Africa. She holds a B.Sc. degree in Biochemistry and Hebrew.

ABOUT 5AM VENTURES

Founded in 2002, 5AM actively invests in next-generation life science companies. With over \$1.4 billion under management, 5AM has invested in 71 companies including Arvinas (NASDAQ: ARVN), Audentes Therapeutics (NASDAQ: BOLD), Cidara Therapeutics (NASDAQ: CDTX), Crinetics Pharmaceuticals (NASDAQ: CRNX), DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (NASDAQ: FLXN), Homology Medicines (NASDAQ: FIXX), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa (acquired by Vifor Pharma). For more information, please visit www.5amventures.com.

CONTACT

5AM Venture Management LLC
Coren Tamboli, Investor Relations Coordinator
Email: coren@5amventures.com